Cardiac Hypertrophy and Fibrosis in the Metabolic Syndrome: A Role for Aldosterone and the Mineralocorticoid Receptor
Obesity and hypertension, major risk factors for the metabolic syndrome, render individuals susceptible to an increased risk of cardiovascular complications, such as adverse cardiac remodeling and heart failure. There has been much investigation into the role that an increase in the renin-angiotensi...
Saved in:
Main Authors: | Eric E. Essick, Flora Sam |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | International Journal of Hypertension |
Online Access: | http://dx.doi.org/10.4061/2011/346985 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
by: Chien‐Wei Huang, et al.
Published: (2025-02-01) -
Mineralocorticoid axis activity and cardiac remodeling in patients with ACTH-dependent Cushing’s syndrome
by: Peter Wolf, et al.
Published: (2025-01-01) -
Role of glucocorticoid receptor expression in Chronic Chagas Cardiomyopathy: implications for inflammation and cardiac hypertrophy
by: Florencia B. González, et al.
Published: (2025-01-01) -
Collecting duct NCOR1 controls blood pressure by regulating mineralocorticoid receptor
by: Ke Sun, et al.
Published: (2025-02-01) -
Baicalin Mitigates Cardiac Hypertrophy and Fibrosis by Inhibiting the p85a Subunit of PI3K
by: Lu He, et al.
Published: (2025-01-01)